[CETP inhibitor].
Inazu
A
A
Department of Laboratory Science, School of Health Sciences, Kanazawa University.
Mabuchi
H
H
D000577:Amides; D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control; D001578:Benzopyrans / Q000494:pharmacology / Q000627:therapeutic use; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D002784:Cholesterol / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D006023:Glycoproteins; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy; D007009:Hypolipoproteinemias / Q000188:drug therapy; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D013438:Sulfhydryl Compounds / Q000494:pharmacology / Q000627:therapeutic use
C095995:6-aminocholesterol; D000577:Amides; D001578:Benzopyrans; C506642:CETP protein, human; C106476:CGS 25159; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D004952:Esters; D006023:Glycoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013438:Sulfhydryl Compounds; C411602:dalcetrapib; C049524:6-chloromercuricholesterol; D002784:Cholesterol